FDA Approval of Daraxonrasib Signals a New Era in Pancreatic Cancer Treatment

For decades, pancreatic cancer has been one of the most difficult cancers to treat. Patients and their families have often faced limited treatment options and poor survival rates. Now, a newly approved targeted therapy is offering renewed hope.

The U.S. Food and Drug Administration (FDA) has granted approval to daraxonrasib (Rasonque), a first-of-its-kind oral targeted therapy for adults with metastatic pancreatic adenocarcinoma, the most common form of pancreatic cancer. Experts believe the approval could represent a major turning point in the treatment of this aggressive disease.

According to Kyaw Aung, M.B.B.S., Ph.D., medical oncologist specializing in gastrointestinal cancers, particularly pancreatic cancer, at Baptist Health Herbert Wertheim Cancer Institute, the significance of this approval cannot be overstated.

“This is fantastic news for all pancreatic cancer patients,” Dr. Aung says. “This approval marks a new era for pancreatic cancer treatment.”

Why Pancreatic Cancer Has Been So Challenging to Treat

Pancreatic adenocarcinoma accounts for approximately 90% to 95% of pancreatic cancer cases. The disease is often diagnosed at an advanced stage because symptoms may not appear until the cancer has already spread.

Metastatic pancreatic cancer means the cancer has moved beyond the pancreas to other parts of the body. Historically, treatment has relied heavily on chemotherapy, which uses powerful drugs to kill rapidly growing cancer cells. While chemotherapy can help some patients, it can also cause significant side effects and has offered limited long-term success for many people with advanced disease.

The need for more effective therapies has driven researchers to look for new ways to attack cancer at its molecular roots.

What Makes Daraxonrasib Different?

Unlike traditional chemotherapy, daraxonrasib is a targeted therapy.

Targeted therapies are designed to identify and block specific molecules that help cancer cells grow and survive. By focusing on these cancer-driving mechanisms, targeted treatments may be able to attack tumors more precisely while potentially reducing damage to healthy cells.

Daraxonrasib works by targeting the RAS pathway, one of the most important drivers of pancreatic cancer growth. To understand why this matters, it helps to know a little about the KRAS protein.

Understanding KRAS

KRAS is a protein that acts like an on-off switch inside cells, helping regulate growth and division. In many cancers, including pancreatic cancer, mutations (changes) in the KRAS gene cause the protein to become permanently switched on, allowing cancer cells to grow uncontrollably.

For many years, scientists considered KRAS to be essentially "undruggable" because of its complex structure. Daraxonrasib changes that landscape by targeting activated forms of RAS proteins involved in cancer growth.

“Daraxonrasib is a targeted treatment, not chemotherapy,” Dr. Aung explains. “It works differently from chemotherapy by targeting activated KRAS protein in pancreatic cancer cells.”
The distinction is important because it represents a shift from broadly attacking cancer cells to addressing a key molecular driver of the disease.

Impressive Results from a Large Clinical Trial

The FDA approval was based on findings from the RASolute 302 Phase 3 clinical trial, which included 500 adults with previously treated metastatic pancreatic adenocarcinoma.

Participants received either daraxonrasib or standard chemotherapy, allowing researchers to compare outcomes directly.

The results were striking:

• Median overall survival: 13.2 months with daraxonrasib versus 6.7 months with chemotherapy
• Risk of death: Approximately 60% lower among patients receiving daraxonrasib
• Progression-free survival: Nearly doubled compared with chemotherapy

Median overall survival refers to the point at which half of patients are still alive after treatment. While every patient's experience is different, improvements in this measurement are considered highly meaningful in cancer research.

Progression-free survival measures how long patients live without their cancer worsening.

Together, these results suggest that daraxonrasib may provide substantially better outcomes than existing standard treatments for eligible patients.

Could This Lead to Less Reliance on Chemotherapy?

One of the most exciting aspects of the approval is what it could mean for the future of pancreatic cancer treatment.

For decades, chemotherapy has been the foundation of treatment for advanced pancreatic cancer. The emergence of a successful targeted therapy raises the possibility that future treatment approaches may rely less heavily on traditional chemotherapy.

Dr. Aung believes this approval could be the beginning of a major shift.

“We can now envisage a future with no chemotherapy needed for pancreatic cancer patients,” he says. “This is a remarkable milestone.”

While chemotherapy remains an important treatment option today, researchers are increasingly focused on developing therapies that address the specific genetic and molecular characteristics of tumors.

The success of daraxonrasib may accelerate those efforts.

Who Is Eligible for the New Treatment?

The FDA approval applies to adults with metastatic pancreatic adenocarcinoma who meet the agency's approved criteria for treatment

Because the therapy targets RAS-related cancer pathways, physicians will determine whether a patient is an appropriate candidate based on factors such as their diagnosis, treatment history, and tumor characteristics.

Patients interested in learning whether daraxonrasib may be suitable for them should speak with their oncology team. Treatment decisions are highly individualized and depend on many clinical considerations.

Understanding Possible Side Effects

Like all cancer treatments, daraxonrasib can cause side effects.

Common reported side effects include:

• Rash
• Diarrhea
• Stomatitis (inflammation and soreness inside the mouth)
• Nausea
• Fatigue
• Vomiting
• Abdominal pain
• Edema (swelling caused by fluid buildup)
• Decreased appetite
• Hemorrhage (bleeding)

Rash was among the most frequently reported side effects in clinical studies.

Patients should discuss potential risks and benefits with their healthcare providers and promptly report any new symptoms during treatment.

A Breakthrough Beyond Pancreatic Cancer

The impact of this approval may extend well beyond pancreatic cancer.

KRAS mutations are not unique to pancreatic tumors. Similar genetic changes occur in several other cancers, including lung cancer and colorectal cancer. Because daraxonrasib targets a pathway involved in multiple tumor types, researchers are already exploring how similar approaches might help other patients.

Dr. Aung sees enormous potential ahead.

“KRAS mutations are found in multiple other cancers, including lung cancer and colorectal cancers, and this approval also opens up opportunities for KRAS-targeted treatments for those with other cancers,” he says.

If future research confirms similar benefits, the approval of daraxonrasib could ultimately influence cancer treatment far beyond pancreatic disease.

“We will see significant advances in the near future in KRAS-targeted therapy for other cancer types,” Dr. Aung says.

A New Chapter for Patients and Families

Pancreatic cancer remains one of the most serious cancer diagnoses, with a five-year survival rate that has historically lagged behind many other cancers. For patients facing metastatic disease, treatment advances have often been incremental rather than transformative.

For patients, families, physicians, and researchers, the FDA's decision signals a promising step forward,

The arrival of daraxonrasib represents something different: a new targeted strategy that nearly doubled median survival in a large clinical trial and offers a fresh approach to a cancer that has long resisted innovation.

Click here for more information about cancer treatments and specialists available at Baptist Health Herbert Wertheim Cancer Institute.